Background: Circulating levels of the chitinase-like protein YKL-40 are influenced by genetic variation in its encoding gene (chitinase 3-like 1 [CHI3L1]) and are increased in patients with several diseases, including asthma. Epigenetic regulation of circulating YKL-40 early in life is unknown. Objective: We sought to determine (1) whether methylation levels at CHI3L1 CpG sites mediate the association of CHI3L1 single nucleotide polymorphisms (SNPs) with YKL-40 levels in the blood and (2) whether these biomarkers (CHI3L1 SNPs, methylation profiles, and YKL-40 levels) are associated with asthma in early childhood. Methods: We used data from up to 2405 participants from the Spanish Infancia y Medio Ambiente; the Swedish Barn/ Children, Allergy, Milieu, Stockholm, Epidemiological survey; and the Dutch Prevention and Incidence of Asthma and Mite Allergy birth cohorts. Associations between 68 CHI3L1 SNPs, methylation levels at 14 CHI3L1 CpG sites in whole-blood DNA, and circulating YKL-40 levels at 4 years of age were tested by using correlation analysis, multivariable regression, and mediation analysis. Each of these biomarkers was also tested for association with asthma at 4 years of age by using multivariable logistic regression. Results: YKL-40 levels were significantly associated with 7 SNPs and with methylation at 5 CpG sites. Consistent associations between these 7 SNPs (particularly rs10399931 and rs4950928) and 5 CpG sites were observed. Alleles linked to lower YKL-40 levels were associated with higher methylation levels. Participants with high YKL-40 levels (defined as the highest YKL-40 tertile) had increased odds for asthma compared with subjects with low YKL-40 levels (meta-analyzed adjusted odds ratio, 1.90 [95% CI, 1.08-3.36]). In contrast, neither SNPs nor methylation levels at CpG sites in CHI3L1 were associated with asthma. Conclusions: The effects of CHI3L1 genetic variation on circulating YKL-40 levels are partly mediated by methylation profiles. In our study YKL-40 levels, but not CHI3L1 SNPs Key words: YKL-40, CHI3L1, asthma, epigenetics, DNA methylation, genetics YKL-40, a chitinase-like protein, is upregulated in patients with asthma, cancer, and other diseases characterized by inflammation and tissue remodeling. 1 In adults YKL-40 levels are increased in the blood and lungs of patients with asthma [2] [3] [4] and correlate with lung function deficits, disease severity and persistence. [2] [3] [4] [5] [6] [7] [8] [9] [10] However, to date, findings on YKL-40 and asthma in childhood have been conflicting. [11] [12] [13] The mechanisms linking YKL-40 with asthma remain to be determined, although in vitro and animal studies support its role in T H 2 adaptive immune responses. 14 The association between genetic variation in chitinase 3-like 1 (CHI3L1, the gene encoding YKL-40) and asthma susceptibility/severity suggests a possible causal link. 11, [15] [16] [17] [18] A group of 4 single nucleotide polymorphisms (SNPs) tagged by rs4950928 were first associated with asthma in 3 of 4 tested populations, with the major alleles conferring increased risk. 11 In the same study serum YKL-40 levels were found to be a highly heritable quantitative trait in the general population and to be directly associated with the same C allele at rs4950928 that was associated with asthma risk. Subsequent studies showed that another SNP, rs10399931, which is in strong linkage disequilibrium (LD) with rs4950928, had similar, if not stronger, effects on gene expression, 16 plasma YKL-40 levels, 19 and asthma. 16 However, although the association between CHI3L1 genetic variation and YKL-40 levels has been conclusively established, the relation of CHI3L1 variation to asthma remains controversial because other reports, [20] [21] [22] including a large study of more than 6500 Danish adults, 20 failed to replicate the aforementioned genetic associations with asthma.
Identification of the mechanisms by which genetic variation in CHI3L1 regulates YKL-40 levels might have important implications for understanding the potential effect of this gene on human disease. Epigenetic regulation of gene expression is one of the possible mechanisms by which genetic variation can affect protein levels and disease susceptibility, 23 including childhood respiratory diseases. 24 DNA sequence variants across the genome have been shown to have cis-(and to less extent trans-) effects on methylation levels at specific CpG sites. 23, [25] [26] [27] [28] [29] [30] Yet, to date, no study has addressed DNA methylation as a possible intermediary mechanism of the relation between CHI3L1 genetic variation and upregulated YKL-40 protein levels.
The primary goal of the present study was to determine whether methylation levels at CHI3L1 CpG sites mediate the association of CHI3L1 genetic variation to YKL-40 levels in blood. In secondary analyses we also sought to assess whether the CHI3L1 genotype and methylation levels that regulate YKL-40 levels are associated with asthma in early childhood.
METHODS

Study populations and design
This study was part of the Mechanisms of the Development of Allergy (MeDALL) project, 31 which included analyses on YKL-40 as an a priori biomarker candidate. The design and available data for the present study are summarized in Fig 1. Primary analyses (Fig 1, A) included molecular and phenotypic data from 433 participants who were 4 years of age from the Spanish Infancia y Medio Ambiente (INMA; n 5 203) 32 and the Swedish Barn/Children, Allergy, Milieu, Stockholm, Epidemiological survey (BAMSE; n 5 230) 33 birth cohorts. These children were selected from their original cohorts for epigenetic and YKL-40 studies in MeDALL based on the following sampling strategy. Among participants who provided paired DNA samples at 2 time points (birth and 4 years for INMA and 4 and 8 years for BAMSE), we selected children who had 1 or more of 3 diagnoses (asthma, eczema, and allergic rhinitis) and a similar number of randomly selected control subjects (none of the 3 diagnoses, nested case-control design). Of these children, 172 INMA and 78 BAMSE participants also had available genome-wide association study (GWAS) data.
In secondary analyses of association with asthma (Fig 1, B) , in addition to INMA and BAMSE, we also included 4-year-old participants from the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) study to increase statistical power. 34, 35 No serum YKL-40 levels were available for PIAMA, but epigenetic studies were completed on 193 PIAMA participants who were selected based on the same sampling strategy described previously. For analyses of genetic association, we used data from all participants from the 3 cohorts who had both GWAS data and asthma information (n 5 336 for INMA, n 5 467 for BAMSE, and n 5 1602 for PIAMA; total n 5 2405).
A detailed description of the 3 birth cohorts and additional information on molecular assays are provided in the Methods section in this article's Online Repository at www.jacionline.org. For all cohorts, parents provided written informed consent, and the local ethics review boards approved the performed studies and procedures.
Definition of asthma
In MeDALL an asthma definition 36 was used that included positive answers to at least 2 of the 3 following questions: (1) ''Has your child ever been diagnosed by a doctor as having asthma?''; (2) ''Has your child taken any medicines for asthma (including inhalers, nebulizers, tablets, or liquid medicines) or for breathing difficulties (chest tightness, shortness of breath) in the last 12 months?''; and (3) ''Has your child had wheezing or whistling in their chest at any time in the last 12 months?'' or ''Has your child had breathing difficulties (chest tightness, shortness of breath) in the last 12 months?'' This definition was used for BAMSE and PIAMA. Because information on doctor-diagnosed asthma was not available in INMA, for this cohort, the asthma definition included a positive response to the 2 remaining questions.
Molecular data
DNA methylation assays at CHI3L1 CpG sites. Epigenome-wide analysis scans of paired whole peripheral blood DNA methylation samples at birth and age 4 years in INMA and at age 4 and 8 in BAMSE and PIAMA were generated by using the Illumina Infinium HumanMethylation450 BeadChip assays (Illumina, San Diego, Calif). All samples were quality checked, as described in the Methods section in this article's Online Repository. The Illumina 450K included 485,577 assays. During processing, the probes on sex chromosomes, the probes that mapped on multiloci, 65 SNP assays, and the probes containing SNPs at the target CpG sites with a Table E1 in this article's Online Repository at www.jacionline.org). Two of them (cg17014757 and cg03625911) have probes that include known SNPs with minor allele frequencies of greater than 5% in European populations, as reported by Chen et al. 37 The probe of cg17014757 includes rs10399931 and the probe of cg03625911 includes rs7515776, which, according to the CEU panel of the 1000 Genomes project, is in nearly complete LD with rs10399805. These 2 CpG sites were included in statistical analyses, but associations of their methylation levels with overlapped SNPs or other SNPs in LD with the overlapped SNPs (rs10399931 and rs4950928 for cg17014757 and rs2886117, rs10399805, and rs7542294 for cg03625911) were identified in tables to caution interpretation.
Methylation levels (b values) at a given CpG site were derived from the ratio of the methylated probe intensity and overall intensity (sum of methylated and unmethylated probe intensities). Thus b is equal to M/ (U 1 M1 a), where M is intensity of the methylated probe, U is the intensity of the unmethylated probe, and a is the constant offset with the default value of 100. The intensity has been corrected for type I and type II probe differences and normalized by using the ''dasen'' method in the wateRmelon R package. 38 Results from analyses on methylation levels were also confirmed after adjustment for blood cell-type composition, as predicted by the Houseman algorithm, 39 and, in a subset of 116 INMA participants at year 4, after adjustment for available differential cell counts obtained directly from microscopic inspection of blood smears. The methylation signal of the top 5 CpG sites obtained by using the Illumina microarray was also validated by means of pyrosequencing in whole-blood DNA from 96 subjects participating in the PIAMA study (see the Methods section, Fig E4, and Table E11 in this article's Online Repository at www.jacionline.org).
YKL-40 measurements. Circulating YKL-40 levels were measured in serum (INMA) and plasma (BAMSE) samples at age 4 years by using a commercially available ELISA kit (Quantikine Human CHI3L1 immunoassay; R&D Systems, Abingdon, United Kingdom).
GWAS. Genome-wide genotyping had been previously completed for the 3 cohorts (INMA, BAMSE, and PIAMA) by using various platforms (see the Methods section in this article's Online Repository). For the present study, in the INMA cohort we tested 68 SNPs that were genotyped from the genomic region surrounding (650 kb) CHI3L1 (hg19: chromosome 1: 203,098,059-203,205,922) by using the HumanOmni1-Quad BeadChip (Illumina). SNPs that were found not to be in Hardy-Weinberg equilibrium by using exact tests 40 were filtered (see the Methods section in this article's Online Repository for GWAS assays). SNPs that were significantly associated with YKL-40 levels in INMA were also tested in BAMSE and PIAMA.
Analytic approach and statistical analysis
For the primary goal, we analyzed interrelationships between multilevel biomarkers (SNPs, methylation at CpG sites, and YKL-40 levels) in INMA and BAMSE, according to a stepwise approach (Fig 1, A) . Because results of these analyses did not significantly differ between cases and control subjects, they are presented with no stratification by disease. YKL-40 levels were log-transformed and then standardized within each cohort by subtracting the mean and dividing the result by the SD, as done in previous multicohort studies. Children with complete data on asthma, covariates, and at least 1 of the 3 biomarkers at age 4 years (ie, CHI3L1 SNPs, CHI3L1 methylation, or YKL-40 levels).
Discovery analyses were completed in INMA with a conservative Bonferroni correction and replication analyses in BAMSE with a 1-tailed a value of .05 (ie, only associations with the same direction of effect between the 2 cohorts were tested for significance). First, associations between CHI3L1 SNPs and YKL-40 levels were studied. In INMA 68 SNPs were tested in linear regressions predicting YKL-40 protein levels according to additive genetic models. Because INMA and BAMSE used different GWAS platforms, in BAMSE we used genotyped or imputed SNPs for replication of INMA results as appropriate. Second, methylation levels were tested for correlation with YKL-40 levels by using Spearman correlation coefficients. Third, the SNPs and CpG sites that were found to be related to YKL-40 levels were tested for association with each other using robust regressions to reduce the effect of potential outlier observations (see the Methods section in this article's Online Repository for additional information).
Multivariable regression models with backward stepwise variable selection were used to determine what SNPs and CpG sites were independently related to YKL-40 protein levels. A final mediation analysis was completed in INMA by using the R package ''mediation'' 42 to estimate the effects by the aforementioned independent SNPs on YKL-40 that were mediated by means of methylation. For this analysis, we used both methylation levels at the CpG site (cg07423149) that was identified by using the above backward stepwise selection, as well as the first principal component obtained by using a principal component analysis (PCA) on methylation levels at all 5 CpG sites that were associated with YKL-40. Only SNPs significant after Bonferroni correction are shown (data for all SNPs are shown in Table E3 ). Boldface indicates associations significant after Bonferroni correction. *SNPs are shown according to position in the gene. Hardy-Weinberg equilibrium P value. àCoefficient from additive models predicting standardized YKL-40 levels. §Percentage variability in YKL-40 levels explained by the SNP. For our secondary analyses (Fig 1, B) , we performed separate multiple logistic regression models testing the association of SNPs, CpG methylation levels, and YKL-40 levels with asthma, with adjustment for sex, age, and body mass index at 4 years because these demographic factors can affect methylation and YKL-40 levels, as well as asthma risk. To test for nonlinearity of effects, YKL-40 levels were also used as tertiles, and asthma risks were compared between subjects having medium and high YKL-40 levels and subjects having low YKL-40 levels. Table I shows characteristics of children included in the primary and secondary analyses. Table E2 in this article's Online Repository at www.jacionline.org compares demographic characteristics of participants from the 3 cohorts who were or were not included in the present study.
RESULTS
Primary analyses: Relation between CHI3L1 SNPs, methylation, and YKL-40 levels SNPs and YKL-40 protein levels. Among the 68 tested SNPs, after Bonferroni correction, 7 were found to be significantly associated with YKL-40 levels in INMA (see Table E3 in this article's Online Repository at www.jacionline.org for complete analysis and Table II for significant associations). Overall, minor alleles were associated with higher YKL-40 levels, with the exceptions of rs10399931 and rs4950928. These 7 SNPs explained individually up to 16% of the variability in YKL-40 levels (R 2 5 0.08-0.16), and they did not belong to a single block of LD. The LD matrix of CHI3L1 SNPs in INMA is shown in Fig E1 in this article's Online Repository at www.jacionline.org.
In BAMSE associations with YKL-40 levels were replicated for 5 (rs2886117, rs10399931, rs10399805, rs4950928, and rs7542294) of the 7 SNPs that provided significant signals in INMA (see Table E4 in this article's Online Repository at www. jacionline.org).
DNA methylation and YKL-40 protein levels. Descriptive statistics of methylation levels at the 14 CpG sites are shown in Table E5 Fig 2 and see E4) .
Correlations between methylation levels at CpG sites and YKL-40 levels for INMA and BAMSE are shown in Table III . In INMA serum YKL-40 levels at age 4 years correlated significantly with methylation levels at age 4 years at 8 CpG sites after Bonferroni correction (P 5 3 3 10 216 to .003). All correlations were negative; that is, the higher the methylation, the lower the YKL-40 level. Inverse correlations between methylation and YKL-40 levels at age 4 years were replicated in BAMSE for 5 of these CpG sites (cg13134650, cg07423149, cg17014757, cg14085262, and cg03625911; Fig 2 and Table III) . 43 In addition, methylation levels at these 5 CpG sites, as measured at birth in INMA and at age 8 years in BAMSE, also correlated with YKL-40 levels at age 4 years (Table III and Fig E3 in this article' s Online Repository at www.jacionline.org). These CpG associations with YKL-40 levels were confirmed after adjustment for blood cell composition (data not shown).
At each of these 5 CpG sites, methylation levels obtained by using the microarray and those obtained by means of pyrosequencing were strongly correlated (Spearman correlation coefficients 5 0.60-0.92, see Fig E4) .
SNPs and DNA methylation. Next, we tested associations between the 7 SNPs and the 5 CpG sites that were found to be related to YKL-40 levels in the aforementioned analyses (see Fig  E5 in this article' s Online Repository at www.jacionline.org for a Boldface indicates correlations significant both in the discovery population (INMA, 4 years) after Bonferroni correction and in the replication population (BAMSE, 4 years; 1-sided a 5 .05). Associations in boldface were confirmed after adjustment for blood cell composition. *Probe overlaps known SNPs with minor allele frequencies of greater than 10% (rs10399931). Probe overlaps known SNPs with minor allele frequencies of greater than 10% (rs7515776).
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 map of the CpG genomic locations). In INMA 4-year methylation levels at 4 of 5 CpG sites were significantly associated with all 7 SNPs after Bonferroni correction (Table IV) , with alleles linked to lower YKL-40 levels being associated with higher methylation levels. These genetic associations were remarkably similar when methylation levels from cord blood were analyzed (Table  IV) . Based on the effect estimates and the percentage variability in methylation levels that they explained, the SNPs rs10399931 and rs4950928, which are in strong LD, showed the strongest associations for all 5 CpG sites. These 2 SNPs were also associated with methylation levels at all 5 CpG sites in BAMSE at both age 4 and 8 years (see Table E6 in this article's Online Repository at www.jacionline.org). These 5 CpG sites also showed significant associations with CHI3L1 SNPs and significant correlations between their methylation levels at 4 and 8 years of age in PIAMA (see Fig E6, C, and Table E7 in this article's Online Repository at www.jacionline. org).
Multivariable and mediation analyses. Given the aforementioned associations, we conducted multivariable analyses to identify independent effects by SNPs and CpG sites on YKL-40 levels. Among the 7 SNPs, in INMA the final backward stepwise regression model included rs4950928 and rs7542294, whereas the final model in BAMSE included rs10399931 and rs10399805. Of note, rs4950928 and rs7542294 are in strong LD with rs10399931 and rs10399805, respectively (see Fig E1) , indicating that in both cohorts genetic influences on YKL-40 levels can be driven by these 2 groups of SNPs in LD. Among the 5 CpG sites, final stepwise models predicting YKL-40 levels included only cg07423149 in INMA and only cg17014757 in BAMSE, but it should be noted that methylation levels at the 5 CpG sites were strongly correlated with each other in both INMA (Fig  2; Spearman correlation coefficients 5 0.64-0.87) and BAMSE (Spearman correlation coefficients 5 0.51-0.83, see Fig E3) , making it difficult to determine whether a single CpG site or rather a global regional methylation profile was driving the association with YKL-40 levels. To evaluate the components of methylation profiles across these 5 highly correlated CpG sites, we conducted a PCA and found that the first component explained up to 79% and up to 75% of variance in INMA and BAMSE, respectively.
To evaluate to what extent methylation profiles mediated the relation of CHI3L1 variation to YKL-40 levels, we completed mediation analyses in INMA (the largest cohort with complete data). In these analyses we tested the 2 SNPs (rs4950928 and rs7542294) and the CpG site (cg07423149) identified by using multivariable analyses plus the first component identified from the PCA. In these analyses cg07423149 mediated 62% of the rs4950928 effects and 43% of the rs7542294 effects on YKL-40 levels (see Table E8 in this article's Online Repository at www.jacionline.org). Corresponding percentages for the overall methylation score were only slightly higher (66% and 46%, respectively). These results indicate that CHI3L1 methylation profiles might mediate a substantial proportion of the effects of CHI3L1 genetic variation on YKL-40 levels. Boldface indicates associations significant after Bonferroni correction. *Probe overlaps known SNPs with minor allele frequencies of greater than 10% (rs10399931). Probe overlaps known SNPs with minor allele frequencies of greater than 10% (rs7515776, which is in nearly complete LD with rs10399805). àCoefficient from additive models predicting percentage methylation levels. §Percentage variability in methylation levels explained by the SNP. kAssociation with an SNP overlapped by the CpG probe (or with an SNP in strong LD [r 2 > 0.7] with the overlapped SNP).
Secondary analyses: Associations of 3-level biomarkers (SNPs, methylation, and YKL-40) with asthma
We also tested all the markers (ie, variation at 7 SNPs, methylation at 5 CpG sites at age 4 years, and YKL-40 levels at age 4 years) for cross-sectional associations with asthma using the maximum number of available genetic and epigenetic samples in INMA, BAMSE, and PIAMA. Numbers and characteristics of participants included in these analyses are shown in Table I. Table V shows results of association analyses with asthma for each of the biomarkers. Neither the SNPs nor the CpG sites showed consistent associations with asthma in INMA, BAMSE, and PIAMA. The lack of association between methylation at any of the CpG sites and asthma was also confirmed after further adjustment for blood cell composition (data not shown). In contrast, YKL-40 levels were associated, although weakly, with asthma (Table V) . In metaanalyses each SD increase in YKL-40 level was associated with a borderline 22% increase in the odds for asthma (P 5 .08), and participants in the highest YKL-40 tertile had 90% increased odds for asthma compared with subjects in the lowest tertile (P 5 .03).
In additional analyses we confirmed the lack of association of genetic and epigenetic markers with asthma when methylation levels at the other 9 CpG sites in CHI3L1 were analyzed (see Table  E9 in this article's Online Repository at www.jacionline.org) and when SNPs and methylation levels were tested for associations with the comorbidity cluster (asthma, rhinitis, and eczema) that was recently described 44 in these cohorts (see Table E10 in this article's Online Repository at www.jacionline.org).
DISCUSSION
This is the first study to integrate genetic and epigenetic regulation of YKL-40 levels in childhood. We found consistent interrelationships between CHI3L1 genetic variants, methylation levels at several CHI3L1 CpG sites, and circulating YKL-40 levels. These associations were replicated in multiple independent cohorts. Taken together with our mediation analysis, these data indicate that methylation levels mediate part of the known effects of genetic variation on YKL-40 levels. We also observed an association of YKL-40 levels, but not CHI3L1 SNPs or methylation levels, with asthma.
YKL-40 has been proposed as a potential biomarker for a broad range of diseases. 1 Increased levels of YKL-40 have been consistently found in the blood and airways of adults with asthma, particularly those with severe and persistent disease. 2, 3, [5] [6] [7] [8] [9] [10] The underlying mechanisms of these associations remain largely to be determined. In vitro studies have shown that human bronchial epithelial cells express CHI3L1 and secrete YKL-40 in response to mechanical stress similar to that experienced during bronchoconstriction. 45 Furthermore, YKL-40 levels were increased in bronchoalveolar lavage fluid from patients with asthma on segmental allergen challenge. 46, 47 In support of a possible causal involvement of this gene in asthma, Chi3l1-null mice showed decreased aeroallergen-induced T H 2 inflammatory responses in their lungs compared with wild-type animals. 10 Whereas the link between YKL-40 levels and asthma has been consistently reported in adults, results from asthma studies in children have been conflicting. Serum YKL-40 levels at birth and in the first 5 years of life were not significantly associated with asthma at age 6 years in 2 studies, although positive trends were observed in both cases. 11, 48 Serum YKL-40 levels were increased in children with therapy-resistant asthma, 12 but no association between YKL-40 levels and asthma severity was found in a subsequent study of 61 asthmatic children. 13 In our larger study we found children with asthma to have increased circulating YKL-40 levels, although this association was relatively weak. This might be due to the fact that we studied population-based epidemiologic cohorts in which the prevalence of severe asthma is expected to be quite low. Circulating YKL-40 levels have been previously described to be under strong genetic control. In multivariable analyses we found SNPs from 2 groups of LD to be independently associated with serum YKL-40 levels. Among them, the 2 SNPs rs10399931 and rs4950928 fell within a single LD block and were identified as the strongest protein quantitative trait loci in our study, which is consistent with previous reports. 11, 49 They are located in proximity of the transcription start site, and because they are in strong LD, it is difficult to dissect their independent effects on YKL-40 levels and disease risk. Gene reporter assays for CHI3L1 promoter haplotypes indicated that both SNPs contributed significant cisregulatory effects on gene expression in Jurkat cells and that the magnitude of these effects was the strongest for rs10399931, 16 which was also the SNP with the strongest effects on methylation levels in our study.
Findings from our study indicate that the effects of CHI3L1 SNPs on circulating YKL-40 levels might be mediated by methylation levels at CHI3L1 CpG sites. Several SNPs were associated with methylation levels at 5 CpG sites located within 1 kb of the transcription start site that were, in turn, negatively correlated with YKL-40 levels. It should be noted that the probe for cg17014757 includes rs10399931 and the probe for cg03625911 includes rs7515776. Therefore the strong associations that were found between methylation levels at these CpG sites and the corresponding SNPs (or other SNPs in LD with them) might be due to allele-specific differences in probe hybridization. 37 However, similar genetic associations, although smaller in magnitude than those observed for cg17014757, were found for CpG sites (ie, cg13134650, cg07423149, and cg14085262), the probes of which do not include known SNPs. Mediation analyses that were completed both on cg07423149 and on the methylation principal component supported SNP/CpG/YKL-40 causal models.
Our findings are in line with a growing body of evidence that points to significant effects of DNA sequence variants across the genome on methylation levels at nearby and distal CpG sites. 23, [25] [26] [27] [28] [29] [30] Previous studies have shown that these methylation quantitative trait loci (meQTLs) can in turn affect gene expression 25, 50 and are enriched in motifs for DNA-binding factors and DNaseI hypersensitivity regions. 29, 51 meQTLs have been shown to be enriched for disease risk variants, 29 and they can ultimately influence disease risk through their effects on methylation patterns. 23, 28 Similarly, CHI3L1 meQTLs could influence asthma risk by affecting methylation, gene expression, and, in turn, YKL-40 levels. However, in contrast with this scenario, in our study neither CHI3L1 SNPs nor methylation at CHI3L1 CpG sites were associated with asthma, although YKL-40 levels tended to be higher in children with asthma. These results have 2 alternate explanations: either they represent a true negative finding, which would argue against a causal role of CHI3L1 variants in childhood asthma, or they are due to possible methodological factors that should be taken into account. First, asthma, particularly in the preschool years, is characterized by a large phenotypic heterogeneity that can affect our ability to capture phenotype-specific genetic associations. Along the same lines, the lack of genetic associations can be explained by CHI3L1 influencing asthma risk through interactions with environmental factors or through effects on asthma phenotypes that were not included or were underrepresented in our study (eg, adult or severe asthma). It is also possible that our genetic association analyses were underpowered to detect a true signal, although in that case the magnitude of the CHI3L1 genetic effects would be expected to be relatively small. Our study has some limitations. Although we did not find any statistical evidence that interrelationships between CHI3L1 genetic variation, methylation, and YKL-40 levels differed between cases and control subjects, these stratified analyses had limited sample size, and potential differences by disease status could not be determined conclusively. The methylation array that we used is primarily designed for genomic discovery. Thus information from a large proportion of CHI3L1 CpG sites and, in turn, analyses on regional methylation profiles could not be included in our study and will need to be addressed in future studies. Finally, we acknowledge that, by using whole blood for methylation studies, we might have missed contributions of methylation profiles from other tissues (eg, from the airways), and our results might have been affected by blood cell composition, particularly in analyses that used cord blood. 52 However, it should be noted that we were able to replicate all the associations between methylation at the 5 CpG sites and serum YKL-40 levels after adjustment for blood cell composition, both as estimated by using the Houseman method and, in a subset of INMA participants, as directly assessed from blood smears.
In conclusion, in multiple independent cohorts we found genetic variation in the CHI3L1 gene to be related to both methylation levels in nearby CpG sites and circulating YKL-40 levels. Our findings indicate that CHI3L1 genetic variation can affect circulating YKL-40 levels by regulating its gene methylation profiles.
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